Medical Affairs

Our mission is to engineer highly effective devices that deliver exceptional outcomes and position ProSomnus as the premier non-CPAP therapy for Obstructive Sleep Apnea (OSA).

Market Access
(US & Intl)

  • 510(k)’s
  • K1027
  • Licenses/Registration non-US Jurisdictions (Canada, CE Mark, etc.)
  • Coding, Billing & Reimbursement (whatever we think is applicable, but doesn’t suggest any specific reimbursement rates)

Scientific Affairs & Studies

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam consectetur, magna in cursus ultricies, purus sapien aliquam nisi, nec vehicula nunc libero et velit. Integer at arcu ac nunc iaculis dignissim.

Public Health Mission

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam consectetur, magna in cursus ultricies, purus sapien aliquam nisi, nec vehicula nunc libero et velit. Integer at arcu ac nunc iaculis dignissim.

Precision Oral Appliance

A precision oral appliance is an innovative medical device that is FDA-cleared to treat Obstructive Sleep Apnea (OSA) and snoring(1). Unlike other oral appliances, a precision oral appliance is entirely crafted from the patient’s oral records with no pre-made components, ensuring a comfortable fit and optimal effectiveness.

Hyo-glossal Repositioning

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam consectetur, magna in cursus ultricies, purus sapien aliquam nisi, nec vehicula nunc libero et velit. Integer at arcu ac nunc iaculis dignissim.

Materials Matter

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nullam consectetur, magna in cursus ultricies, purus sapien aliquam nisi, nec vehicula nunc libero et velit. Integer at arcu ac nunc iaculis dignissim.

Applicant Form

Thank you for your interest in ProSomnus career opportunities. Please choose your department of interest:

Resume Upload

By submitting this form, you may be contacted by our staff to verify information.

Brian Dow

Chief Financial Officer

Brian Dow is the Chief Financial Officer for ProSomnus® Sleep Technologies. Prior to joining ProSomnus in March of 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.

Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.

Request Your Provider Portal Login Credentials

Please complete the form. A ProSomnus team member will reach out to you with your unique login credentials.

Request an Appointment